Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.

Percent of breast cancer patients per age group was similar for low-, intermediate-, and high-risk score in patients 41–70 years old, but there was an increasing trend toward high-risk score in patients younger than 40 and older than 70 years of age.

also in 63,971 other papers